915770-55-7

Basic information

• Product Name: Benzamide, 3-chloro-2,4-difluoro-N-(2-hydroxyethyl)-N-methyl-
• CAS NO: 915770-55-7
• Molecular Formula: C10H10ClF2NO2
• Molecular Weight: 249.645
• Mol File: 915770-55-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Benzamide, 3-chloro-2,4-difluoro-N-(2-hydroxyethyl)-N-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 3-chloro-2,4-difluoro-N-(2-hydroxyethyl)-N-methyl-(915770-55-7)
• EPA Substance Registry System: Benzamide, 3-chloro-2,4-difluoro-N-(2-hydroxyethyl)-N-methyl-(915770-55-7)

Safety Data

• Hazardous Substances Data: 915770-55-7(Hazardous Substances Data)

Upstream product

• 109-83-1 (2-hydroxyethyl)(methyl)amine 
• 157373-00-7 3-chloro-2,4-difluoro-benzoyl chloride 

Downstream Products

• 915771-76-5 1,1-dimethylethyl 3-[({3-[(1-methylethyl)oxy]-5-[(4-methyl-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-8-yl)oxy]phenyl}carbonyl)amino]-1H-pyrazole-1-carboxylate 
• 915771-74-3 methyl 3-[(9-chloro-4-methyl-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-8-yl)oxy]-5-[(phenylmethyl)oxy]benzoate 
• 915771-78-7 methyl 3-[(1-methylethyl)oxy]-5-[(4-methyl-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-8-yl)oxy]benzoate 
• 915771-79-8 1-methylethyl 3-[(1-methylethyl)oxy]-5-[(4-methyl-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-8-yl)oxy]benzoate 
• 915771-73-2 methyl 3-hydroxy-5-[(4-methyl-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-8-yl)oxy]benzoate 
• 915770-53-5 3-[(9-chloro-4-methyl-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepin-8-yl)oxy]-5-[(1S)-2-hydroxy-1-methylethoxy]-N-(1-methyl-1H-pyrazol-3-yl)benzamide 
• 1020854-96-9 3-[(11-chloro-5-methyl-6-oxo-2-oxa-5-azabicyclo[5.4.0]undeca-8,10,12-trien-10-yl)oxy]-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide 

Relevant articles and documents

CHEMICAL COMPOUNDS

The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).